Considering the crucial role of p53 in cancer development and dissemination, p53-targeted therapies are amongst the most encouraging anticancer strategies. Inactivation of p53 by interaction with murine double minute (MDM)2 and MDMX is a common event in human cancers bearing wild-type (wt) p53. Consistently, simultaneous inhibition of the p53 interaction with both MDMs is crucial for full p53 reactivation in cancer.
